Robert L. Schlossman | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Robert L. Schlossman is active.

Explore More

Publication

Featured researches published by Robert L. Schlossman.

Journal of Immunology | 1997

IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.

Atsushi Ogata; Dharminder Chauhan; Gerrard Teoh; Steven P. Treon; Mitsuyoshi Urashima; Robert L. Schlossman; Kenneth C. Anderson

Blood | 1996

Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein

Mitsuyoshi Urashima; Atsushi Ogata; Dharminder Chauhan; Maria Belen Vidriales; Gerrard Teoh; Yasutaka Hoshi; Robert L. Schlossman; James A. DeCaprio; Kenneth C. Anderson

Seminars in Oncology | 1999

Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.

Steven P. Treon; Yoshihito Shima; Frederic I. Preffer; Deborah Doss; Leonard Ellman; Robert L. Schlossman; Michael L. Grossbard; Andrew R. Belch; Linda M. Pilarski; Kenneth C. Anderson

Blood | 2007

Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.

Irene M. Ghobrial; Renee Leduc; Marybeth Nelson; Xavier Leleu; Eric Jacobsen; Ann LaCasce; Daniel J. DeAngelo; David C. Fisher; Jennifer R. Brown; Robert L. Schlossman; Diane Warren; Jacob D. Soumerai; Kelly O’Connor; Nikhil M. Munshi; Paul G. Richardson; Kenneth C. Anderson; Thomas E. Witzig; Steven P. Treon

Archive | 2013

marrow milieu Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone

Dharminder Chauhan; Kenneth C. Anderson; Teru Hideshima; Masaharu Akiyama; Toshiaki Hayashi; Paul G. Richardson; Robert L. Schlossman

Archive | 2013

in First Complete Remission CD6-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukemia

Andrea Freeman; Karen C. Marcus; Peter Mauch; Lee Nadler; Lini Bartlett-Pandite; David C. Fisher; Robert L. Schlossman; Richard Stone; Christine Murray; Robert J. Soiffer; Diane L. Fairclough; Michael J. Robertson; Edwin P. Alyea; Kenneth C. Anderson

Archive | 2013

receptor associated with antibody response to BCMA, a plasma-cell membrane Graft-versus-tumor response in patients with multiple myeloma is

Jerome Ritz; Bingyan Wu; Christine Canning; Robert L. Schlossman; Nikhil C. Munshi; Kenneth C. Anderson; Roberto Bellucci; Edwin P. Alyea; Sabina Chiaretti; Catherine J. Wu; Emmanuel Zorn; Edie Weller

Archive | 2013

bortezomib with refractory multiple myeloma who have received lenalidomide and Phase 1 study of pomalidomide MTD, safety, and efficacy in patients

Min Chen; Mohamad H. Zaki; Christian Jacques; Laura McBride; Elizabeth Bilotti; Palka Anand; Lisa Nardelli; Gail Larkins; Daniel C. Sullivan; Melissa Alsina; Robert L. Schlossman; Im Ghobrial; Deborah Doss; Paul G. Richardson; David S. Siegel; Rachid Baz; Susan L. Kelley; Nikhil C. Munshi; Jacob Laubach

Archive | 2013

microenvironment migration of multiple myeloma cells in the bone marrow GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and

Teru Hideshima; Dharminder Chauhan; Kenneth C. Anderson; Renate Burger; Robert L. Schlossman; Paul G. Richardson; Lini Pandite; Laurence Catley; Reshma Shringarpure; Pedro Carvalho

Archive | 2013

well tolerated in patients with relapsed multiple myeloma Immunomodulatory drug CC-5013 overcomes drug resistance and is

Kathe Balinski; Jerome B. Zeldis; Kenneth C. Anderson; Julie Mechlowicz; Andrea Freeman; Reggie Deocampo; Joan J. Ryoo; Richard LeBlanc; Laurence Catley; Deborah Doss; Kathleen A. Kelly; Mary McKenney; Paul G. Richardson; Robert L. Schlossman; Edie Weller; Teru Hideshima; Constantine S. Mitsiades

Explore More